# A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

> **NCT00616798** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 323 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** RO4917838
- **DRUG:** RO4917838
- **DRUG:** RO4917838
- **DRUG:** Placebo
- **DRUG:** Standard antipsychotic therapy

## Key facts

- **NCT ID:** NCT00616798
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 323 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616798, "A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00616798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*